Top Clinical Trials companies in Singapore by Debt to Equity Ratio

This ranking features the top 2 Clinical Trials companies in Singapore ranked by Debt to Equity Ratio, averaging a Debt to Equity Ratio of 0.44, for February 08, 2025.

Singapore

Clinical Trials
Debt to Equity Ratio
#
Name
Debt to Equity Ratio
 Reported Date
Stock Price
Change
 Price (30 days) Country
1
WVE

Wave Life Sciences Ltd.

1

WVE
0.68
Dec. 31, 2023 USD 11.57 -4.06%

Singapore
2
950210.KS

Prestige BioPharma Limited

2

950210.KS
0.20
June 30, 2024 USD 10.41 0.13%

Singapore
Frequently Asked Questions
  • Which Clinical Trials company in Singapore has the highest Debt to Equity Ratio ?

    The Clinical Trials company in Singapore with the highest Debt to Equity Ratio is Wave Life Sciences Ltd. (NasdaqGM: WVE) at 0.68.

  • Which Clinical Trials company in Singapore has the lowest Debt to Equity Ratio ?

    The Clinical Trials company in Singapore with the lowest Debt to Equity Ratio is Prestige BioPharma Limited (KSE: 950210.KS) at 0.20.

SV Wall Street